What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “D-Fi is composed of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.”In the company’s words, NCT06892639 on ClinicalTrials.gov
- Tested for
- Dystrophic Epidermolysis Bullosa
- Main trialPhase 3
- “The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.”In the company’s words, NCT06892639 on ClinicalTrials.gov
Other drugs for Dystrophic Epidermolysis Bullosa
- KB803Krystal Biotech, Inc. · Phase 3
- FCX-007Castle Creek Biosciences, LLC. · Phase 3
- Oleogel-S10Chiesi Farmaceutici S.p.A. · Phase 3
- ENERGI-F703Energenesis Biomedical Co., Ltd. · Phase 2
- TCP-25 gelXinnate AB · Phase 2
- AGLE-102Aegle Therapeutics · Phase 1/2
Coming up1
- Sep 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Sep 2027 | Evaluation of D-Fi for the Treatment of Wounds Due to DEB |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026